| Title |
Biomarkers for primary biliary cholangitis: current perspectives
|
|---|---|
| Published in |
Hepatic medicine evidence and research, June 2018
|
| DOI | 10.2147/hmer.s135337 |
| Pubmed ID | |
| Authors |
Elias Kouroumalis, Demetrius Samonakis, Argyro Voumvouraki |
| Abstract |
Primary biliary cholangitis (PBC) is a chronic progressive cholestatic disease characterized by destruction of small- and medium-sized intrahepatic bile ducts. It is no longer a rare disease, since many new asymptomatic cases are incidentally identified. Liver biopsy is diagnostically critical but not always feasible or practical to be performed. Many potential, noninvasive, markers have been proposed to replace liver biopsy and further provide the assessment of disease severity and ultimate prognosis. In this review, we evaluated serum biomarkers proposed for diagnosis, extent of fibrosis, disease prognosis and attempts for early prediction of treatment response. Older biochemical and immunological markers are presented along with recent reports including the role of microRNAs and promising results based on proteomics and metabolomics. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 31 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 5 | 16% |
| Student > Ph. D. Student | 4 | 13% |
| Student > Bachelor | 3 | 10% |
| Student > Postgraduate | 3 | 10% |
| Student > Master | 2 | 6% |
| Other | 5 | 16% |
| Unknown | 9 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 39% |
| Agricultural and Biological Sciences | 3 | 10% |
| Immunology and Microbiology | 3 | 10% |
| Biochemistry, Genetics and Molecular Biology | 2 | 6% |
| Unspecified | 1 | 3% |
| Other | 2 | 6% |
| Unknown | 8 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 February 2022.
All research outputs
#7,856,238
of 25,584,565 outputs
Outputs from Hepatic medicine evidence and research
#31
of 105 outputs
Outputs of similar age
#125,077
of 343,364 outputs
Outputs of similar age from Hepatic medicine evidence and research
#2
of 2 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 105 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 343,364 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one.